Carol Cronenberger

691 total citations
28 papers, 540 citations indexed

About

Carol Cronenberger is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Rheumatology. According to data from OpenAlex, Carol Cronenberger has authored 28 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 13 papers in Pediatrics, Perinatology and Child Health and 8 papers in Rheumatology. Recurrent topics in Carol Cronenberger's work include Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical studies and practices (13 papers) and Alzheimer's disease research and treatments (7 papers). Carol Cronenberger is often cited by papers focused on Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical studies and practices (13 papers) and Alzheimer's disease research and treatments (7 papers). Carol Cronenberger collaborates with scholars based in United States, United Kingdom and Germany. Carol Cronenberger's co-authors include Kevin Sweeney, Haiqing Dai, Steve Riley, Michael K. Smith, Wonkyung Byon, P Chan, Jing Dong, Ana Ruiz-Garcı́a, Brendon Binneman and Jaren W. Landen and has published in prestigious journals such as Annals of the Rheumatic Diseases, British Journal of Clinical Pharmacology and Drug Metabolism and Disposition.

In The Last Decade

Carol Cronenberger

28 papers receiving 526 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carol Cronenberger United States	13	173	135	135	101	78	28	540
Cindy Kortepeter United States	15	58 0.3×	45 0.3×	54 0.4×	117 1.2×	44 0.6×	30	787
Matt Hutmacher United States	11	77 0.4×	57 0.4×	22 0.2×	40 0.4×	69 0.9×	15	618
Michael Heathman United States	12	45 0.3×	41 0.3×	46 0.3×	113 1.1×	26 0.3×	24	604
María Talegón Spain	15	164 0.9×	48 0.4×	64 0.5×	78 0.8×	32 0.4×	17	408
Christian Leporini Italy	14	155 0.9×	62 0.5×	32 0.2×	54 0.5×	67 0.9×	24	715
Atkinson Aj United States	6	47 0.3×	81 0.6×	42 0.3×	35 0.3×	23 0.3×	10	525
Himanshu Naik United States	14	210 1.2×	40 0.3×	73 0.5×	86 0.9×	215 2.8×	37	748
Kyoko Matsuguma Japan	12	39 0.2×	86 0.6×	163 1.2×	64 0.6×	27 0.3×	16	636
Teun M. Post Netherlands	9	26 0.2×	54 0.4×	44 0.3×	61 0.6×	19 0.2×	18	551
Jai N. Patel United States	20	54 0.3×	179 1.3×	63 0.5×	43 0.4×	6 0.1×	95	1.0k

Countries citing papers authored by Carol Cronenberger

Since Specialization

Citations

This map shows the geographic impact of Carol Cronenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Cronenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Cronenberger more than expected).

Fields of papers citing papers by Carol Cronenberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Cronenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Cronenberger. The network helps show where Carol Cronenberger may publish in the future.

Co-authorship network of co-authors of Carol Cronenberger

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Cronenberger. A scholar is included among the top collaborators of Carol Cronenberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Cronenberger. Carol Cronenberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dagenais, Simon, et al.. (2024). Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population. Clinical and Translational Science. 17(3). e13741–e13741. 2 indexed citations

Fleischmann, Roy, Sharad Lakhanpal, Donna S. Cox, et al.. (2023). Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study. The Lancet Rheumatology. 5(9). e532–e541. 8 indexed citations

Fleischmann, Roy, et al.. (2022). Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and Therapy. 9(3). 839–850. 4 indexed citations

Cox, Donna S., et al.. (2021). Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(10). 1166–1173. 3 indexed citations

Fleischmann, Roy, et al.. (2021). Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial. Arthritis Research & Therapy. 23(1). 248–248. 12 indexed citations

Wolbink, Gertjan, et al.. (2020). Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?. BioDrugs. 34(6). 723–732. 28 indexed citations

Fleischmann, Roy, et al.. (2020). AB0289 EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26. Annals of the Rheumatic Diseases. 79. 1443–1444. 2 indexed citations

Cohen, Stanley, S. Radominski, Hideto Kameda, et al.. (2020). Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial. BioDrugs. 34(2). 197–207. 12 indexed citations

Sweeney, Kevin, et al.. (2019). Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 85(3). 487–499. 7 indexed citations

10.

Alten, Rieke, Vira Tseluyko, Tomas Hala, et al.. (2018). FRI0137 Efficacy, safety and immunogenicity from week 30 to week 54 in a randomised, double-blind phase iii study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab. Annals of the Rheumatic Diseases. 77. 612–613. 3 indexed citations

11.

Fleischmann, Roy, Rieke Alten, Margarita Pileckytė, et al.. (2018). A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Arthritis Research & Therapy. 20(1). 178–178. 42 indexed citations

12.

Cohen, Stanley, et al.. (2018). Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis. Arthritis Care & Research. 70(11). 1598–1606. 22 indexed citations

13.

Landen, Jaren W., Sharon Cohen, Clare B. Billing, et al.. (2017). Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy. Alzheimer s & Dementia Translational Research & Clinical Interventions. 3(3). 339–347. 50 indexed citations

14.

Byon, Wonkyung, Michael K. Smith, P Chan, et al.. (2013). Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance. CPT Pharmacometrics & Systems Pharmacology. 2(7). 1–8. 152 indexed citations

15.

Miyoshi, Izuru, Yoko Fujimoto, Qinying Zhao, et al.. (2013). Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimerâs disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. International Journal of Clinical Pharmacology and Therapeutics. 51(12). 911–923. 20 indexed citations

16.

Cronenberger, Carol, Kathryn Wright, Kelly R. Bales, et al.. (2012). P1‐012: Effect of ponezumab on CSF biomarkers: Pooled analysis of phase IIa studies in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_3). 18 indexed citations

17.

Landen, Jaren W., Niels Andreasen, Carol Cronenberger, et al.. (2012). P4‐209: Safety, tolerability, pharmacokinetics and pharmacodynamics of monthly and quarterly doses of Ponezumab (PF‐04360365) in subjects with mild‐to‐moderate Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_19). 3 indexed citations

18.

Kraynov, Eugenia, Steven W. Martin, Susan Hurst, et al.. (2011). How Current Understanding of Clearance Mechanisms and Pharmacodynamics of Therapeutic Proteins Can Be Applied for Evaluation of Their Drug-Drug Interaction Potential. Drug Metabolism and Disposition. 39(10). 1779–1783. 14 indexed citations

19.

Cronenberger, Carol, et al.. (2007). Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokers. British Journal of Clinical Pharmacology. 65(1). 30–39. 24 indexed citations

20.

Lalka, David, et al.. (1993). The Hepatic First‐Pass Metabolism of Problematic Drugs. The Journal of Clinical Pharmacology. 33(7). 657–669. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact